Hypoglycemia Increases Risk of Cognitive Dysfunction in Type 2 Diabetes, finds study
Researchers have established that hypoglycemic events independently contribute to the risk of cognitive dysfunction in individuals living with Type 2 diabetes mellitus (T2DM). A recent study has replicated an extensive analysis of more than 3.9 million participants, indicating a 47% increased risk for cognitive dysfunction among participants with hypoglycemia compared to those without the condition. The study was published in Frontiers in Neurology journal by Min Ye and colleagues.
Type 2 diabetes mellitus has been widely recognized as a critical risk factor for cognitive dysfunction, a condition that can considerably affect life quality. However, the role of hypoglycemic events, which result from poor glycemic control, has been a subject of increasing debate in terms of vulnerability. Although there is a suggested association between hypoglycemia and cognitive dysfunction in various literatures, the nature of the association, in particular, how it could follow a dose-response pattern, has not been appropriately established. Therefore, the study aimed to determine the contribution of hypoglycemic episodes to developing cognitive dysfunction in T2DM patients and investigate the dose-response relationship between them.
Authors searched nine major databases from their inception to May 2023 for observational studies evaluating the association between hypoglycemia and cognitive dysfunction. A total of 17 articles with 30 studies including 3,961,352 participants were included for review. The pooled risk ratio and 95% CI are estimated by the DerSimonian-Laird method. In addition, a dose-response analysis was performed to investigate the potential relationship between the frequency of hypoglycemic attacks and the risk of cognitive dysfunction.
Results
• This analysis showed that hypoglycemic patients had a significantly higher risk of developing cognitive dysfunction.
• The combined RR of the association between hypoglycemia and cognitive dysfunction was 1.47 (95% CI: 1.35-1.60), with evidence of a 47% increased risk for cognitive impairment among patients experiencing hypoglycemic attacks.
• Episode of Hypoglycemia: The pooled RR for cognitive dysfunction was 1.20( 95% CI 1.11-1.31), which implies that there is a 20% increased likelihood of cognitive dysfunction.
• Two Episodes of Hypoglycemia: The pooled RR further increased, at 1.41 (95% CI 1.05-1.88), with a 41% higher risk of cognitive dysfunction.
• Three or More Episodes of Hypoglycemia: The pooled RR increased further, at 1.62 (95% CI 1.20-2.91), representing a 62% increased likelihood of cognitive dysfunction.
• The dose-response analysis showed that hypoglycemic episodes are linearly associated with cognitive dysfunction, with an increased likelihood of 17.87% with every additional episode of hypoglycemia (exp(b) = 1.178694, z = 7.12, p < 0.001).
This study concludes that hypoglycemic events are significantly associated with the risk of cognitive dysfunction in patients with T2DM. Every additional hypoglycemic episode increases the risk of cognitive impairment. The results have shown that effective management of blood glucose, screening for cognitive dysfunction, and health education for the prevention of hypoglycemia and its long-term consequences on cognition are of great importance.
Reference
